Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ALPMY's Cash to Debt is ranked higher than
95% of the 1173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. ALPMY: No Debt )
ALPMY' s 10-Year Cash to Debt Range
Min: 3.62   Max: No Debt
Current: No Debt

Equity to Asset 0.74
ALPMY's Equity to Asset is ranked higher than
81% of the 983 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ALPMY: 0.74 )
ALPMY' s 10-Year Equity to Asset Range
Min: 0.73   Max: 0.78
Current: 0.74

0.73
0.78
Interest Coverage 70.45
ALPMY's Interest Coverage is ranked higher than
65% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 133.58 vs. ALPMY: 70.45 )
ALPMY' s 10-Year Interest Coverage Range
Min: 66.96   Max: 9999.99
Current: 70.45

66.96
9999.99
F-Score: 8
Z-Score: 6.92
M-Score: -3.45
WACC vs ROIC
6.13%
14.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 13.53
ALPMY's Operating margin (%) is ranked higher than
82% of the 1117 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. ALPMY: 13.53 )
ALPMY' s 10-Year Operating margin (%) Range
Min: 10.25   Max: 28.37
Current: 13.53

10.25
28.37
Net-margin (%) 9.98
ALPMY's Net-margin (%) is ranked higher than
80% of the 1117 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.55 vs. ALPMY: 9.98 )
ALPMY' s 10-Year Net-margin (%) Range
Min: 7.09   Max: 18.24
Current: 9.98

7.09
18.24
ROE (%) 9.65
ALPMY's ROE (%) is ranked higher than
76% of the 1157 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.46 vs. ALPMY: 9.65 )
ALPMY' s 10-Year ROE (%) Range
Min: 4.6   Max: 16.06
Current: 9.65

4.6
16.06
ROA (%) 7.27
ALPMY's ROA (%) is ranked higher than
81% of the 1183 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.53 vs. ALPMY: 7.27 )
ALPMY' s 10-Year ROA (%) Range
Min: 3.71   Max: 12.27
Current: 7.27

3.71
12.27
ROC (Joel Greenblatt) (%) 46.13
ALPMY's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 1178 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.83 vs. ALPMY: 46.13 )
ALPMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 30.35   Max: 91.95
Current: 46.13

30.35
91.95
Revenue Growth (3Y)(%) -0.60
ALPMY's Revenue Growth (3Y)(%) is ranked higher than
62% of the 971 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. ALPMY: -0.60 )
ALPMY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 9.2
Current: -0.6

0
9.2
EBITDA Growth (3Y)(%) -3.00
ALPMY's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ALPMY: -3.00 )
ALPMY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 5.5
Current: -3

0
5.5
EPS Growth (3Y)(%) 3.40
ALPMY's EPS Growth (3Y)(%) is ranked higher than
73% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. ALPMY: 3.40 )
ALPMY' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 55.4
Current: 3.4

0
55.4
» ALPMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALPMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.40
ALPMY's P/E(ttm) is ranked higher than
80% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 58.60 vs. ALPMY: 33.40 )
ALPMY' s 10-Year P/E(ttm) Range
Min: 7.26   Max: 53.2
Current: 33.4

7.26
53.2
Forward P/E 5.92
ALPMY's Forward P/E is ranked higher than
99% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALPMY: 5.92 )
N/A
PE(NRI) 32.90
ALPMY's PE(NRI) is ranked higher than
83% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 57.50 vs. ALPMY: 32.90 )
ALPMY' s 10-Year PE(NRI) Range
Min: 7.26   Max: 53.2
Current: 32.9

7.26
53.2
P/B 2.80
ALPMY's P/B is ranked higher than
75% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. ALPMY: 2.80 )
ALPMY' s 10-Year P/B Range
Min: 0.34   Max: 3.25
Current: 2.8

0.34
3.25
P/S 4.11
ALPMY's P/S is ranked higher than
61% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. ALPMY: 4.11 )
ALPMY' s 10-Year P/S Range
Min: 0.55   Max: 10.2
Current: 4.11

0.55
10.2
PFCF 35.60
ALPMY's PFCF is ranked higher than
84% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 701.67 vs. ALPMY: 35.60 )
ALPMY' s 10-Year PFCF Range
Min: 6.29   Max: 99.85
Current: 35.6

6.29
99.85
POCF 22.73
ALPMY's POCF is ranked higher than
85% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.21 vs. ALPMY: 22.73 )
ALPMY' s 10-Year POCF Range
Min: 4.77   Max: 36.78
Current: 22.73

4.77
36.78
EV-to-EBIT 20.51
ALPMY's EV-to-EBIT is ranked higher than
84% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.19 vs. ALPMY: 20.51 )
ALPMY' s 10-Year EV-to-EBIT Range
Min: 0.7   Max: 90.9
Current: 20.51

0.7
90.9
Shiller P/E 29.90
ALPMY's Shiller P/E is ranked higher than
86% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALPMY: 29.90 )
ALPMY' s 10-Year Shiller P/E Range
Min: 17.5   Max: 33.87
Current: 29.9

17.5
33.87
Current Ratio 2.45
ALPMY's Current Ratio is ranked higher than
74% of the 1051 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. ALPMY: 2.45 )
ALPMY' s 10-Year Current Ratio Range
Min: 2.38   Max: 3.64
Current: 2.45

2.38
3.64
Quick Ratio 2.09
ALPMY's Quick Ratio is ranked higher than
76% of the 1051 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. ALPMY: 2.09 )
ALPMY' s 10-Year Quick Ratio Range
Min: 1.99   Max: 3.22
Current: 2.09

1.99
3.22
Days Inventory 162.24
ALPMY's Days Inventory is ranked higher than
66% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 145.57 vs. ALPMY: 162.24 )
ALPMY' s 10-Year Days Inventory Range
Min: 89.8   Max: 144.8
Current: 162.24

89.8
144.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.79
ALPMY's Dividend Yield is ranked higher than
65% of the 696 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. ALPMY: 0.79 )
ALPMY' s 10-Year Dividend Yield Range
Min: 1.28   Max: 4.39
Current: 0.79

1.28
4.39
Dividend Payout 0.29
ALPMY's Dividend Payout is ranked higher than
86% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALPMY: 0.29 )
ALPMY' s 10-Year Dividend Payout Range
Min: 0.68   Max: 16.19
Current: 0.29

0.68
16.19
Dividend growth (3y) 2.60
ALPMY's Dividend growth (3y) is ranked higher than
70% of the 478 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. ALPMY: 2.60 )
ALPMY' s 10-Year Dividend growth (3y) Range
Min: 1.3   Max: 52.5
Current: 2.6

1.3
52.5
Yield on cost (5-Year) 0.88
ALPMY's Yield on cost (5-Year) is ranked higher than
63% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. ALPMY: 0.88 )
ALPMY' s 10-Year Yield on cost (5-Year) Range
Min: 1.41   Max: 4.85
Current: 0.88

1.41
4.85
Share Buyback Rate -6.70
ALPMY's Share Buyback Rate is ranked higher than
62% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. ALPMY: -6.70 )
ALPMY' s 10-Year Share Buyback Rate Range
Min: 0   Max: -7.1
Current: -6.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 53.60
ALPMY's Price/Net Current Asset Value is ranked higher than
74% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALPMY: 53.60 )
ALPMY' s 10-Year Price/Net Current Asset Value Range
Min: 0.82   Max: 6.6
Current: 53.6

0.82
6.6
Price/Tangible Book 4.20
ALPMY's Price/Tangible Book is ranked higher than
73% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. ALPMY: 4.20 )
ALPMY' s 10-Year Price/Tangible Book Range
Min: 0.48   Max: 4.04
Current: 4.2

0.48
4.04
Price/DCF (Projected) 1.80
ALPMY's Price/DCF (Projected) is ranked higher than
90% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALPMY: 1.80 )
ALPMY' s 10-Year Price/DCF (Projected) Range
Min: 0.23   Max: 3.97
Current: 1.8

0.23
3.97
Price/Median PS Value 2.60
ALPMY's Price/Median PS Value is ranked higher than
50% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. ALPMY: 2.60 )
ALPMY' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 6.35
Current: 2.6

0.37
6.35
Price/Peter Lynch Fair Value 1.50
ALPMY's Price/Peter Lynch Fair Value is ranked higher than
95% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ALPMY: 1.50 )
ALPMY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.42   Max: 1.68
Current: 1.5

0.42
1.68
Price/Graham Number 2.50
ALPMY's Price/Graham Number is ranked higher than
83% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.30 vs. ALPMY: 2.50 )
ALPMY' s 10-Year Price/Graham Number Range
Min: 0.34   Max: 2.37
Current: 2.5

0.34
2.37
Earnings Yield (Greenblatt) 4.90
ALPMY's Earnings Yield (Greenblatt) is ranked higher than
80% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ALPMY: 4.90 )
ALPMY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 145.1
Current: 4.9

1.1
145.1
Forward Rate of Return (Yacktman) 25.26
ALPMY's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.55 vs. ALPMY: 25.26 )
ALPMY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.6   Max: 26.7
Current: 25.26

4.6
26.7

Analyst Estimate

Mar15
EPS($) 1.90
EPS without NRI($) 1.90

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:4503.Japan, YPH.Germany,
Astellas Pharma Inc was incorporated on March 20, 1939. The Company and its subsidiaries are engaged in the manufacturing, marketing of pharmaceuticals products. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis in the topical immunomodulator class; Vesicare, a treatment for overactive bladder; Harnal, an a1 blocking agent for the treatment of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The Company's products also comprise Geninax, an oral quinolone antibacterial agent; Celecox, a selective COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, an antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. The Company also offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI.
» More Articles for ALPMY

Headlines

Articles On GuruFocus.com
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
IVA International Fund Q4 2014 Review Mar 31 2015 
IVA International Fund 2014 Annual Commentary Jan 02 2015 
IVA Worldwide Fund 2014 Annual Commentary Jan 02 2015 
A Look at Global Investor Charles De Vaulx's Top 5 Holdings Dec 02 2014 
IVA International Fund Q3 2014 Review Oct 29 2014 
Charles de Vaulx’s IVA Worldwide Fund Q3 2014 Review Oct 29 2014 
First Eagle Global Fund Q3 2014 Commentary Oct 28 2014 
First Eagle Overseas Fund Q3 2014 Commentary Oct 28 2014 

More From Other Websites
Astellas' Myrbetriq for Overactive Bladder Efficient as Add-On - Analyst Blog May 18 2015
Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin... May 17 2015
Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological... May 17 2015
Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and... May 14 2015
Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual... May 05 2015
Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology... Apr 21 2015
Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog Apr 08 2015
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog Apr 06 2015
Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function Apr 06 2015
MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute... Apr 03 2015
Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival... Apr 02 2015
Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog Mar 26 2015
Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog Mar 26 2015
Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the... Mar 24 2015
Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog Mar 23 2015
New Enzalutamide Data To Be Presented In Late Breaking News Plenary Session At European Association... Mar 16 2015
United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog Mar 11 2015
Astellas' Cresemba Gains FDA Approval, Under Review in EU - Analyst Blog Mar 09 2015
Ironwood Commences Dosing in Phase I Study on IW-1973 - Analyst Blog Mar 06 2015
Antibiotic Croissants; How Matinas Could Revolutionize the War Against Superbugs Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK